COMMUNIQUÉS West-GlobeNewswire
-
Financière de Tubize - Investor call - 23/03/2026 - 17:00 CET
11/03/2026 -
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
11/03/2026 -
Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite
11/03/2026 -
Inc. Names Commure’s Deepika Bodapati to Its 2026 Female Founders 500 List
11/03/2026 -
Nelipak Announces Opening of Asia-Pacific Technical Development Center
11/03/2026 -
Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone
11/03/2026 -
Albanian-Finnish Startup Bliss Raises $270K to Build Culturally Intelligent AI for Therapy
11/03/2026 -
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
11/03/2026 -
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026 -
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026 -
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026 -
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026 -
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026 -
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
11/03/2026 -
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026 -
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
11/03/2026 -
Lighter. Cheaper. Funner. Pub Light Is Here.
11/03/2026 -
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
11/03/2026 -
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026
Pages